Web-based Genetic Research on Parkinson’s Disease

Overview

The purpose of this study is to examine how genes and environment affect risk for Parkinson's disease.

Full Title of Study: “Ongoing, Web-Based Genome-Wide Association Studies for Targeted Disease Initiatives”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: January 2025

Detailed Description

23andMe has created a web-based Parkinson's research initiative to understand the genetic associations found between Parkinson's patients' DNA and their disease. To learn more, visit: https://www.23andme.com/pd/. You can participate in this research initiative without leaving home. If you are eligible to participate, we will send you an in-home 23andMe DNA kit at no cost. We will ask you short online surveys (15-20) about your Parkinson's journey, symptoms, and response to treatment. Enrollment is on-going and open to individuals who have been diagnosed with Parkinson's disease and are residents of the U.S. Participants receive access to ancestry information and uninterpreted genetic data. Participants will also receive regular updates on our research efforts and findings.

Arms, Groups and Cohorts

  • Parkinson’s disease patients
    • People diagnosed with Parkinson’s disease by a physician

Clinical Trial Outcome Measures

Primary Measures

  • Saliva DNA test and online surveys with questions about Parkinson’s disease experience, symptoms and response to treatment
    • Time Frame: Intermittent surveys every 6 months for up to 24 months
    • We want to learn how genes and environment could play role in Parkinson’s disease risk and progression

Participating in This Clinical Trial

Inclusion Criteria

  • diagnosis of Parkinson's disease by a physician

Exclusion Criteria

  • diagnoses other than Parkinson's, including:
  • progressive supranuclear palsy (PSP)
  • multiple system atrophy (MSA)
  • Shy-Drager syndrome
  • spinal cerebella ataxia (SCA)
  • atypical parkinsonism
  • parkinsonism due to medications, drug-induced parkinsonism
  • vascular parkinsonism
  • frontotemporal dementia with parkinsonism

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • 23andMe, Inc.
  • Collaborator
    • Michael J. Fox Foundation for Parkinson’s Research
  • Provider of Information About this Clinical Study
    • Sponsor

Citations Reporting on Results

Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U, Mountain JL, Goldman SM, Tanner CM, Langston JW, Wojcicki A, Eriksson N. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet. 2011 Jun;7(6):e1002141. doi: 10.1371/journal.pgen.1002141. Epub 2011 Jun 23.

Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, Maraganore DM, Martin ER, Martinez M, Myers RH, Nalls MA, Pankratz N, Payami H, Satake W, Scott WK, Sharma M, Singleton AB, Stefansson K, Toda T, Tung JY, Vance J, Wood NW, Zabetian CP; 23andMe Genetic Epidemiology of Parkinson's Disease Consortium; International Parkinson's Disease Genomics Consortium; Parkinson's Disease GWAS Consortium; Wellcome Trust Case Control Consortium 2), Young P, Tanzi RE, Khoury MJ, Zipp F, Lehrach H, Ioannidis JP, Bertram L. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet. 2012;8(3):e1002548. doi: 10.1371/journal.pgen.1002548. Epub 2012 Mar 15.

Pichler I, Del Greco M F, Gögele M, Lill CM, Bertram L, Do CB, Eriksson N, Foroud T, Myers RH; PD GWAS Consortium, Nalls M, Keller MF; International Parkinson's Disease Genomics Consortium; Wellcome Trust Case Control Consortium 2, Benyamin B, Whitfield JB; Genetics of Iron Status Consortium, Pramstaller PP, Hicks AA, Thompson JR, Minelli C. Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS Med. 2013;10(6):e1001462. doi: 10.1371/journal.pmed.1001462. Epub 2013 Jun 4. Erratum in: PLoS Med. 2013 Jun;10(6). doi:10.1371/annotation/c4d81646-0c0e-4a3e-9425-b220bae2d8b6.

Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI); 23andMe; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson's Disease Consortium; Alzheimer Genetic Analysis Group, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014 Sep;46(9):989-93. doi: 10.1038/ng.3043. Epub 2014 Jul 27.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.